A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma.

Trial Profile

A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2014

At a glance

  • Drugs Selumetinib (Primary) ; Temozolomide
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Mar 2013 Planned end date changed from 1 Apr 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
    • 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to an AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top